fda semaglutide warning november 2025 Shares in Novo Nordisk, the Danish firm best known for its Wegovy and Ozempic weight loss drugs, have plunged after it called a halt to closely-watched trials on a treatment for Alzheimer's FDA Decisions Expected: November 2025

The challenge is adherence and achieving sufficient results without additional support

Reducing this risk is a key part of our commitment to driving change for this community, as we work to increase manufacturing capacity to responsibly supply this important medicine. The FDA decision is based on the results of the landmark SELECT phase 3 cardiovascular outcomes trial that examined the effect of adding Wegovy 2.4 mg or placebo to cardiovascular standard of care in adults with overweight and obesity with established CVD and without diabetes

4000 mg L-Carnitine per serving

Lower middle panel : common anticholinergic adverse effects, including blurred vision, tachycardia, urinary retention, constipation, and dry mouth